Coherus BioSciences, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • CHRS
  • 1d0.68%
  • 1w3.56%
  • 1m3.74%
  • 1y-16.92%
ATH
  • ATH Price$37.46
  • ATH Date2015-07-22
  • % since ATH-52.67%
  • % to ATH111.28%
ATL
  • ATL Price$8.35
  • ATL Date2017-11-17
  • % from ATL112.34%
  • Last Low Price$8.35
  • Last Low Date2017-11-17
  • % From Last Low112.34%
IPO
  • IPO Price$0.00
  • % Current ROI USDN/A
  • ATH Price$37.46
  • % ROI ATH 44,862.28%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="CHRS"]

Key Data [addtoany]

Current price $17.73
Sector Healthcare
Industry Biotechnology
Today's High/Low $18.02/$17.62
Volume 1,320,858.00
Previous Close $17.61
52 Week High/Low $23.43/$10.8616
Market Cap 1,257,280,384.00
P/E Ratio 8.49
Forward P/E 1 Yr. $9.93
Earnings Per Share(EPS) $1.11
Annualized Dividend $0
$17.73
[addtoany]

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States.
The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States.
Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar; and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity